Lombard Odier Asset Management (Switzerland) Sa Kura Oncology, Inc. Transaction History

Lombard Odier Asset Management (Switzerland) Sa

$1.14 Billion
Q3 2024

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$10.71 - $14.6 $715,706 - $975,659	-66,826 Reduced 37.02%	113,674 $1.39 Million
Q4 2022 Feb 14, 2023	SELL	$11.23 - $16.9 $425,235 - $639,935	-37,866 Reduced 17.34%	180,500 $2.24 Million
Q3 2022 Nov 14, 2022	SELL	$12.01 - $19.45 $191,043 - $309,391	-15,907 Reduced 6.79%	218,366 $2.98 Million
Q2 2022 Aug 15, 2022	SELL	$10.71 - $18.33 $1,060 - $1,814	-99 Reduced 0.04%	234,273 $4.29 Million
Q1 2022 May 16, 2022	BUY	$11.78 - $16.98 $187,007 - $269,557	15,875 Added 7.27%	234,372 $3.77 Million
Q4 2021 Feb 14, 2022	BUY	$12.22 - $19.57 $225,850 - $361,692	18,482 Added 9.24%	218,497 $3.06 Million
Q3 2021 Nov 12, 2021	BUY	$15.42 - $21.72 $904,675 - $1.27 Million	58,669 Added 41.51%	200,015 $3.75 Million
Q2 2021 Aug 13, 2021	BUY	$20.85 - $29.88 $772,555 - $1.11 Million	37,053 Added 35.53%	141,346 $2.95 Million
Q1 2021 May 17, 2021	BUY	$24.75 - $39.14 $2.58 Million - $4.08 Million	104,293 New	104,293 $2.95 Million

Others Institutions Holding KURA

# of Institutions

185

Shares Held

81.8M

Call Options Held

42.1K

Put Options Held

34K

Suvretta Capital Management, LLC New York, NY

7.65M
Shares

$69 Million
5.88% of portfolio
Black Rock Inc. New York, NY

6.97M
Shares

$62.8 Million
0.0% of portfolio
Eco R1 Capital, LLC San Francisco, CA

5.81M
Shares

$52.3 Million
4.92% of portfolio
Deerfield Management Company, L.P. (Series C) New York, NY

5.41M
Shares

$48.8 Million
1.97% of portfolio
Paradigm Biocapital Advisors LP New York, NY

4.33M
Shares

$39 Million
3.05% of portfolio

View Full List

About Kura Oncology, Inc.

Ticker KURA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 66,893,000
Market Cap $603M
Description
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A p...

More about KURA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Lombard Odier Asset Management (Switzerland) Sa, based on Form 13F filings with the SEC.

News

Stay updated on Lombard Odier Asset Management (Switzerland) Sa with notifications on news.

Account